Cell Dissemination in Pancreatic Cancer - PubMed
- ️Sat Jan 01 2022
Review
Cell Dissemination in Pancreatic Cancer
Jungsun Kim. Cells. 2022.
Abstract
Pancreatic cancer is a disease notorious for its high frequency of recurrence and low survival rate. Surgery is the most effective treatment for localized pancreatic cancer, but most cancer recurs after surgery, and patients die within ten years of diagnosis. The question persists: what makes pancreatic cancer recur and metastasize with such a high frequency? Herein, we review evidence that subclinical dormant pancreatic cancer cells disseminate before developing metastatic or recurring cancer. We then discuss several routes by which pancreatic cancer migrates and the mechanisms by which pancreatic cancer cells adapt. Lastly, we discuss unanswered questions in pancreatic cancer cell migration and our perspectives.
Keywords: adherens junctions; cell dissemination; collective cell migration; epithelial–mesenchymal transition (EMT).
Conflict of interest statement
The authors declare no conflict of interest.
Figures

Cancer cell migration in the pancreas. (A) Topographical view of venous drainage of the pancreas. The portal vein is formed by the confluence of the superior mesenteric, splenic, inferior mesenteric, pancreaticoduodenal, and gastric veins. The tail and body of the pancreas drain into the splenic vein. The head and neck of the pancreas drain into the superior and inferior pancreaticoduodenal veins [44]. (B,C) Depiction of pancreatic ductal cells. Exfoliated cells invade the extracellular matrix by breaking down basement membrane proteins. Migration of exfoliated cells through the ductal lumen (L) is not common but is occasionally seen in pancreatic cancer. The invading PDAC cells can further interact with nerve (B) or venous systems (C) in the pancreata. The use of anatomical diagrams of the pancreas and veins were granted from Elsevier (copyright) [44] and modified using Adobe illustrator and BioRender.
Similar articles
-
Sannino G, Armbruster N, Bodenhöfer M, Haerle U, Behrens D, Buchholz M, Rothbauer U, Sipos B, Schmees C. Sannino G, et al. Oncotarget. 2016 Nov 8;7(45):73725-73738. doi: 10.18632/oncotarget.12455. Oncotarget. 2016. PMID: 27713160 Free PMC article.
-
Kuwada K, Kagawa S, Yoshida R, Sakamoto S, Ito A, Watanabe M, Ieda T, Kuroda S, Kikuchi S, Tazawa H, Fujiwara T. Kuwada K, et al. J Exp Clin Cancer Res. 2018 Dec 11;37(1):307. doi: 10.1186/s13046-018-0981-2. J Exp Clin Cancer Res. 2018. PMID: 30537992 Free PMC article.
-
Zhang Z, Xu Y. Zhang Z, et al. Mol Med. 2022 Jul 19;28(1):82. doi: 10.1186/s10020-022-00509-1. Mol Med. 2022. PMID: 35854234 Free PMC article.
-
The epithelial to mesenchymal transition in pancreatic cancer: A systematic review.
Beuran M, Negoi I, Paun S, Ion AD, Bleotu C, Negoi RI, Hostiuc S. Beuran M, et al. Pancreatology. 2015 May-Jun;15(3):217-25. doi: 10.1016/j.pan.2015.02.011. Epub 2015 Mar 7. Pancreatology. 2015. PMID: 25794655 Review.
-
Epithelial-mesenchymal transition in pancreatic cancer: Is it a clinically significant factor?
Jiang JH, Liu C, Cheng H, Lu Y, Qin Y, Xu YF, Xu J, Long J, Liu L, Ni QX, Yu XJ. Jiang JH, et al. Biochim Biophys Acta. 2015 Jan;1855(1):43-9. doi: 10.1016/j.bbcan.2014.11.004. Epub 2014 Nov 26. Biochim Biophys Acta. 2015. PMID: 25432020 Review.
Cited by
-
Role of exosomes in non-small cell lung cancer and EGFR-mutated lung cancer.
Rao DY, Huang DF, Si MY, Lu H, Tang ZX, Zhang ZX. Rao DY, et al. Front Immunol. 2023 Apr 12;14:1142539. doi: 10.3389/fimmu.2023.1142539. eCollection 2023. Front Immunol. 2023. PMID: 37122754 Free PMC article. Review.
-
Mancha S, Horan M, Pasachhe O, Keikhosravi A, Eliceiri KW, Matkowskyj KA, Notbohm J, Skala MC, Campagnola PJ. Mancha S, et al. Acta Biomater. 2024 Oct 1;187:212-226. doi: 10.1016/j.actbio.2024.08.026. Epub 2024 Aug 23. Acta Biomater. 2024. PMID: 39182805
-
Lu J, Yu L, Xie N, Wu Y, Li B. Lu J, et al. J Cancer. 2023 Apr 17;14(7):1117-1131. doi: 10.7150/jca.84070. eCollection 2023. J Cancer. 2023. PMID: 37215454 Free PMC article.
-
Eade AV, Friedman LR, Larrain C, Rainey A, Hernandez JM, Chawla A, Ferrone CR. Eade AV, et al. Ann Surg Oncol. 2024 Oct;31(10):6373-6374. doi: 10.1245/s10434-024-15817-5. Epub 2024 Jul 24. Ann Surg Oncol. 2024. PMID: 39048905 No abstract available.
-
Atanasova KR, Perkins CM, Ratnayake R, Jiang J, Chen QY, Schmittgen TD, Luesch H. Atanasova KR, et al. Front Pharmacol. 2024 Mar 6;15:1335246. doi: 10.3389/fphar.2024.1335246. eCollection 2024. Front Pharmacol. 2024. PMID: 38510657 Free PMC article.
References
-
- Jones R.P., Psarelli E.-E., Jackson R., Ghaneh P., Halloran C., Palmer D.H., Campbell F., Valle J.W., Faluyi O., O’Reilly D.A., et al. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial. JAMA Surg. 2019;154:1038–1048. doi: 10.1001/jamasurg.2019.3337. - DOI - PMC - PubMed
-
- Groot V.P., Rezaee N., Wu W., Cameron J.L., Fishman E., Hruban R.H., Weiss M.J., Zheng L., Wolfgang C.L., He J. Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma. Ann. Surg. 2018;267:936–945. doi: 10.1097/SLA.0000000000002234. - DOI - PubMed
Publication types
MeSH terms
Grants and funding
JK has been supported by the Knight CEDAR (68182-947-000) from the Cancer Early Detection Advanced Research Center at Oregon Health & Science University’s Knight Cancer Institute, CRUK-OHSU Project Award (2018-CRUK-OHSU-001), and MRF New Investigator Grant (GCNCR1042A).
LinkOut - more resources
Full Text Sources
Medical